When to Test C-Peptide and Fasting Insulin
Routine testing of fasting insulin and C-peptide is NOT recommended for most patients with diabetes or at risk for diabetes—these tests are primarily research tools. 1
Specific Clinical Indications for C-Peptide Testing
1. Ambiguous Diabetes Classification
C-peptide should be measured when clinical presentation makes it difficult to distinguish between type 1 and type 2 diabetes, particularly in patients who have a type 2 phenotype but present in diabetic ketoacidosis 1, 2. However, even in these situations, response to drug therapy often provides sufficient information, making C-peptide measurement not strictly necessary 2.
- Timing consideration: C-peptide is most useful 3-5 years after diagnosis when persistent substantial insulin secretion suggests type 2 or monogenic diabetes rather than type 1 3
- Interpretation: Absent C-peptide at any time confirms absolute insulin requirement and appropriateness of type 1 diabetes management strategies 3
2. Insurance Authorization for Insulin Pump Therapy
If required by the payer for insulin pump coverage, measure fasting C-peptide when simultaneous fasting plasma glucose is ≤220 mg/dL (≤12.5 mmol/L) 1, 2. This is an administrative rather than clinical indication.
3. Investigation of Hypoglycemia
C-peptide measurement is essential when investigating nondiabetic hypoglycemia, specifically to:
- Rule out surreptitious insulin administration (C-peptide will be suppressed with exogenous insulin) 2
- Diagnose insulinoma or islet cell tumors (inappropriately elevated insulin and C-peptide with low glucose) 2
- Evaluate the proinsulin-to-insulin ratio in suspected islet cell tumors 2
Fasting Insulin Testing
Fasting insulin measurement has even more limited clinical utility than C-peptide:
- NOT recommended for routine diabetes care or cardiovascular disease risk assessment 1
- NOT recommended for polycystic ovary syndrome evaluation—physical signs of insulin resistance (BMI, acanthosis nigricans) are more practical 2
- Primary utility is in diagnosing insulinoma when inappropriately elevated insulin persists with low glucose 2
Important Caveats
Common pitfalls to avoid:
- Do not order these tests for "insulin resistance" assessment in routine practice—clinical parameters are more useful
- C-peptide can be measured in fasting state or after glucagon stimulation, but fasting is typically sufficient for clinical decisions 2
- Stimulated C-peptide (after mixed-meal tolerance test) may detect residual beta-cell function in an additional 10% of patients compared to fasting alone, but this is primarily relevant for research 4
- Insulin levels can be underestimated in hemolyzed samples, making C-peptide more reliable 5
The key principle: These tests answer specific diagnostic questions (type 1 vs type 2, hypoglycemia etiology, insurance requirements) rather than guiding routine diabetes management decisions.